Abstract
Background People with two or more underlying chronic conditions (multimorbidity) are more susceptible to adverse events following surgery. This study used -omics methods to compare samples from people with or without multimorbidity in a cardiac surgery cohort.
Methods and Results Measurements of the myocardial transcriptome and metabolites involved in energy production were performed in 53 and 57 sequential participants, respectively. Untargeted analysis of the metabolome in blood and myocardium was performed in 30 sequential participants. Mitochondrial respiration in circulating monocytes was measured in 63 participants. Ninety-eight of 144 participants (68%) had multimorbidity. Three major processes were affected by multimorbidity: innate immune response, DNA damage and associated epigenetic changes, and mitochondrial energy production. The innate immune response was upregulated in multimorbidity and most of the included comorbidities. The DNA damage, epigenetic changes, and aspects of mitochondrial function were specific for multimorbidity. Histone 2B, its ubiquitination enzymes and AKT3 were upregulated in the multimorbid group, supporting our hypothesis of senescence-like changes in multimorbidity. In addition, senescence-associated secretory phenotype analytes, IL-1β, its receptor, GM-CSF and fractalkine increased with the number of accumulating comorbidities. DNA damage was confirmed by independent immunohistochemistry experiments, which also identified nucleolar instability as more prominent in the multimorbid myocardium.
Conclusions Multimorbidity in people with cardiovascular disease is characterized by biological aging processes that are known to increase susceptibility to metabolic stress. These present novel therapeutic targets for organ protection interventions.
Competing Interest Statement
All authors have disclosed that they do not have any potential conflicts of interest.
Funding Statement
This work was supported by Van Geest Foundation, Leicester NIHR Biomedical Research Centre, British Heart Foundation [CH/12/1/29419, AA18/3/34220].
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
ObCard was approved by The East Midlands Nottingham 1 Research Ethics Committee.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
The following aspects of the paper were corrected/updated: 1. Minor mistakes in the text and figures. 2. Additional analysis of untargeted metabolomics. 3. Post-operative analysis of metabolites and mitochondrial respiration was removed to focus on preoperative variables. 4. Additional information on patient recruitment.
